2021
The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology 2021, 6: eabf4034. PMID: 34739340, DOI: 10.1126/sciimmunol.abf4034.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsPD-1 blockadeRegulatory T cell functionImmune checkpoint blockadeCheckpoint blockade immunotherapyT cell responsesT cell functionBlockade immunotherapyAdverse eventsAntitumor immunityCheckpoint blockadeCell responsesBlockadeCell functionAutoimmunityMechanistic featuresEdged swordImmunotherapyTumorsCancerImmunityCirculating clonally expanded T cells reflect functions of tumor-infiltrating T cells
Lucca LE, Axisa PP, Lu B, Harnett B, Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. Journal Of Experimental Medicine 2021, 218: e20200921. PMID: 33651881, PMCID: PMC7933991, DOI: 10.1084/jem.20200921.Peer-Reviewed Original ResearchConceptsTumor-infiltrating T cellsT cellsUnique transcriptional patternsFeatures of exhaustionLongitudinal immune monitoringPeripheral immune environmentsT cell responsesT cell functionSingle-cell levelTranscriptional patternsTCR sharingTerminal exhaustionImmune environmentImmune monitoringCancer immunotherapyMetastatic melanomaEffector functionsCell responsesTumor tissueGene signatureTumorsCell functionImmunotherapyTCRαβBlood
2017
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca LE, Hafler DA. Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews 2017, 276: 9-25. PMID: 28258696, PMCID: PMC5338636, DOI: 10.1111/imr.12529.Peer-Reviewed Original ResearchConceptsCheckpoint immunotherapyTumor rejectionCommon adult brain tumorsImmune-related side effectsCheckpoint receptor blockadeCo-inhibitory receptorsIntroduction of immunotherapyT cell exhaustionImmune regulatory pathwaysCo-inhibitory pathwaysAdult brain tumorsPrevention of autoimmunityCentral nervous systemAnti-tumor activityDifferent tumor typesCheckpoint inhibitorsReceptor blockadeAdvanced cancerTherapeutic successBrain tumorsSide effectsImmunotherapyNervous systemTherapeutic efficacyTumor types
2015
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology 2015, 11: 504-514. PMID: 26260659, PMCID: PMC4782584, DOI: 10.1038/nrneurol.2015.139.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsGlioblastoma patientsMultiple immunosuppressive mechanismsMedian overall survivalImmune checkpoint modulatorsBlood-brain barrierTreatment of glioblastomaOverall survivalImmunosuppressive mechanismsAdvanced tumorsClinical benefitImmunotherapeutic agentsConventional therapyCheckpoint modulatorsLung cancerImmune systemPatientsCancerInhibitorsCurrent understandingImmunotherapyPrognosisLymphocytesTherapy
1995
Therapy for Multiple Sclerosis
Weiner H, Hohol M, Khoury S, Dawson D, Hafler D. Therapy for Multiple Sclerosis. Neurologic Clinics 1995, 13: 173-196. PMID: 7739502, DOI: 10.1016/s0733-8619(18)30066-5.Peer-Reviewed Original ResearchConceptsMultiple sclerosisCell-mediated autoimmune diseaseAccumulation of disabilityMultiple sclerosis patientsSymptomatic therapySclerosis patientsAutoimmune responseCentral nervous system myelinAutoimmune diseasesNonspecific modulationImmune systemSclerosisSystem myelinTherapyImmunotherapyPatientsDiseaseMyelin
1992
Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis
Hafler D, Brod S, Weiner H. Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis. Clinical Medicine And The Nervous System 1992, 301-307. DOI: 10.1007/978-1-4471-3184-7_15.Peer-Reviewed Original ResearchMultiple sclerosisT cellsAutoimmune diseasesNervous systemAutoreactive T cellsPatient T cellsCentral nervous systemInitial inductionMyelin basic proteinSpecific immunotherapyImmune targetsWhite matter structuresImmune regulationProteolipid proteinSclerosisMatter structuresDiseaseBasic proteinDestructive processesImmunotherapyDemyelinationInflammationCareful regulation
1991
Immunotherapy in autoimmune diseases
Miller A, Hafler D, Weiner H. Immunotherapy in autoimmune diseases. Current Opinion In Immunology 1991, 3: 936-940. PMID: 1793539, DOI: 10.1016/s0952-7915(05)80017-2.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunomodulatory therapeutic approachesHuman autoimmune diseasesMajor histocompatibility complex moleculesReceptor gene productsT cell recognitionHistocompatibility complex moleculesImmune interventionImmunological toleranceTherapeutic approachesAnimal modelsDiseaseImmunotherapyTrimolecular complexMolecular basis
1988
Immunotherapy of multiple sclerosis
Weiner H, Hafler D. Immunotherapy of multiple sclerosis. Annals Of Neurology 1988, 23: 211-222. PMID: 3288084, DOI: 10.1002/ana.410230302.Peer-Reviewed Original ResearchConceptsMultiple sclerosisClinical trialsHelper/inducer cellsOnset of progressionMultiple sclerosis therapyNumber of relapsesPresent treatment modalitiesAntigen-specific cellsActivated T cellsImmune balanceImmunotherapeutic interventionsNonspecific immunosuppressionSclerosis therapyAcute attacksAutoimmune diseasesInducer cellsLymphocyte trafficTreatment modalitiesSuppressor influencesEarly treatmentT cellsEffective treatmentTherapeutic goalsImmunotherapyImmune system